S1 Ep221: Redefining Lymphoma Standards of Care: Top Datasets From ASCO and EHA 2026
About this episode
Matthew Matasar discusses practice-changing data on lymphoma management from recent oncology conferences.
In this episode of Oncology On the Go, CancerNetwork® joined Matthew Matasar, MD, chief of the Division of Blood Disorders at Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center, and professor of medicine at Rutgers Robert Wood Johnson Medical School, as he dove into the practice-changing data reshaping the management of aggressive and indolent B-cell lymphomas. Fresh off the presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2026 European Hematology Association (EHA) Congress , Matasar broke down the most talked-about datasets in the field. Matasar began by sharing his expert clinical perspectives on the phase 3 frontMIND trial (NCT04824092) evaluating tafasitamab (Monjuvi) plus lenalidomide (Revlimid) and rituximab (Rituxan) with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL), which were concurrently published in The Lancet .1,2 He assessed how to balance the regimen’s progression-free survival benefit against incremental toxicities and scheduling demands. Furthermore, the conversation explored encouraging data regarding bispecific…
More episodes of Oncology On The Go
- S1 Ep225: How Will Orca-T Impact the Hematologic Oncology Paradigm?
- S1 Ep224: Managing Insomnia in Cancer Care: Sleep Hygiene, CBT-I, and Medications
- S1 Ep222: How Does a Death Doula Support Patients With Cancer?
- S1 Ep223: Optimizing Frontline Selection and Treatment-Free Remission in CML
- S1 Ep220: Exploring The Future of Artificial Intelligence and Thoracic Oncology
- S1 Ep219: Navigating Personality Disorders in Cancer Care
Explore listener stats, chart rankings, contacts and more on the Oncology On The Go podcast page.